Exclusive Provider for Libtayo

Onco360 selected to be the exclusive specialty pharmacy network partner for Regeneron’s new product LIBTAYO^® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. LIBTAYO is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) and is the first and only treatment specifically approved and available for advanced CSCC in the U.S.

“Onco360 is proud to be the single-source provider for this exciting treatment option for advanced CSCC patients,” said President and CEO Paul Jardina. “These patients often have advanced disease with extremely limited treatment options. With the FDA approval of LIBTAYO, we can immediately deliver this key treatment to CSCC patients across the nation.”

CSCC is the second most common form of skin cancer in the United States. While 95% of patients are cured with surgical resection alone, a small subset of patients develops incurable locally advanced or metastatic disease which is no longer amenable to surgery or radiation therapy. For this population, there were previously no FDA-approved systemic treatment options.

LIBTAYO (cemiplimab-rwlc) was approved by The U.S. Food and Drug Administration (FDA) on September 28, 2018 based on clinical data from the Phase II EMPOWER-CSCC study, published in the New England Journal of Medicine¹. More information can be found at libtayo.com.

¹Ascierto PA, et al. Lancet Oncol. 2016;17:1248-1260